Vanguard Group Inc Mersana Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,377,767 shares of MRSN stock, worth $3.18 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,377,767
Previous 7,057,516
18.71%
Holding current value
$3.18 Million
Previous $10.1 Million
71.78%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding MRSN
# of Institutions
116Shares Held
101MCall Options Held
16.3KPut Options Held
13K-
Nextech Invest Ag12.1MShares$4.59 Million3.22% of portfolio
-
Nextech Invest, Ltd. Zurich, V812.1MShares$4.59 Million0.97% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$3.29 Million0.99% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$3.19 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.61MShares$2.89 Million0.02% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $36.9M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...